In monotherapy clinical trials, thyroiditis was more common after blockade of the PD-1/PD-L1 pathway with an incidence of 8–38% compared to CTLA-4 inhibition with an incidence of 6–25% [7,8,9]. Here, CTLA4 is linked to thyroiditis.